Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) had their “neutral” rating restated by Equities research analysts at Edison Group in a research note issued to investors on Thursday, AnalystRatings.Net reports.

The analysts wrote, “Achillion holds the promise of developing an all-oral HCV regimen that can be competitive in the evolving HCV treatment landscape. It is the only small-cap biotech company with HCV drug candidates in three key classes – NS5A, nucleotide NS5B polymerase and protease inhibitors. Early pre- and clinical data for these candidates demonstrated strong potency and favourable drug profiles. Further Phase II clinical trials would provide efficacy data for various combinations, potentially leading to partnerships. Achillion is funded until 2016, after critical Phase II combination data become available: positive data should be a major value inflection point.”

A number of other firms have also recently commented on ACHN. Analysts at Maxim Group upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, March 24th. They now have a $6.00 price target on the stock. Analysts at Zacks downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Thursday, January 30th. They now have a $4.10 price target on the stock. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $5.36.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded down 5.52% on Thursday, hitting $2.91. The stock had a trading volume of 1,125,525 shares. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $8.49. The stock has a 50-day moving average of $3.1 and a 200-day moving average of $3.18. The company’s market cap is $281.7 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings data on Friday, March 7th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.16) by $0.02. Analysts expect that Achillion Pharmaceuticals will post $-0.77 EPS for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

To view Edison Group’s full report, visit Edison Group’s official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.